![Tanya Lewis](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Tanya Lewis
Direktor/Vorstandsmitglied bei
DIAMEDICA THERAPEUTICS INC.
Vermögen: - $ am 31.05.2026
Profil
Tanya N.
Lewis is currently an Independent Director at DiaMedica Therapeutics, Inc. since 2023 and a Director at Sernova Biotherapeutics, Inc. Former roles include Chief Development Operations Officer at Replimune Group, Inc. from 2021 to 2024; Chief Regulatory & Quality Officer, Executive VP at Karyopharm Therapeutics, Inc. from 2019 to 2021; Vice President-Regulatory & Quality Affairs at Syros Pharmaceuticals, Inc. from 2017 to 2018; VP-Regulatory Affairs & Quality Assurance at Idera Pharmaceuticals, Inc. from 2015 to 2016; VP-Regulatory Affairs & Quality Assurance at Tesaro, Inc. from 2011 to 2015; Senior Director-Regulatory Affairs at Millennium Pharmaceuticals, Inc. in 2008; and VP-Regulatory Affairs & Quality Assurance at both Vion Pharmaceuticals, Inc. and Seaside Therapeutics LLC.
Education includes graduate studies at Massachusetts College of Pharmacy & Health Science and undergraduate studies at Northeastern University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 22.05.2026 | 0 ( -.--% ) | - $ | 31.05.2026 | |
| 01.06.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Tanya Lewis
| Unternehmen | Position | Beginn |
|---|---|---|
| DIAMEDICA THERAPEUTICS INC. | Direktor/Vorstandsmitglied | 01.03.2023 |
| SERNOVA BIOTHERAPEUTICS INC | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Tanya Lewis
| Unternehmen | Position | Ende |
|---|---|---|
| REPLIMUNE GROUP, INC. | Direktor/Vorstandsmitglied | 01.05.2021 |
| KARYOPHARM THERAPEUTICS INC. | General Counsel | 01.05.2021 |
| SYROS PHARMACEUTICALS, INC. | General Counsel | 01.07.2018 |
Idera Pharmaceuticals, Inc.
 Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | General Counsel | 01.12.2016 |
| TESARO INC | General Counsel | 01.06.2015 |
Ausbildung von Tanya Lewis
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
54
Beziehungen ersten Grades
12
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 12 |
|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Manufactures medicines for oncology treatment | Health Technology |
Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops drug candidates for oncology and rare disease indications | Health Technology |
Vion Pharmaceuticals, Inc.
 Vion Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops small molecule anticancer compounds | Health Technology |
Sernova Biotherapeutics, Inc.
 Sernova Biotherapeutics, Inc. BiotechnologyHealth Technology Develops life science products | Health Technology |
DiaMedica Therapeutics, Inc.
 DiaMedica Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that engages in development and commercialization of therapeutic treatments from novel recombinant proteins | Health Technology |
Tesaro, Inc.
 Tesaro, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops drugs for cancer patients | Health Technology |
Massachusetts College of Pharmacy & Health Science
 Massachusetts College of Pharmacy & Health Science Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Northeastern University
 Northeastern University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Seaside Therapeutics LLC
 Seaside Therapeutics LLC Medical DistributorsDistribution Services Develops drug treatments to correct or improve the course of fragile x syndrome | Distribution Services |
Karyopharm Therapeutics, Inc.
 Karyopharm Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs for the treatment of cancer, inflammation and other diseases related to cell proliferation | Health Technology |
Syros Pharmaceuticals, Inc.
 Syros Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which developing care for the frontline treatment of patients with hematologic malignancies | Health Technology |
Replimune Group, Inc.
 Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
